Sugi Predict

Sugi Predict / Targets / ALK

ALK

ALK tyrosine kinase receptor · Q9UM73 · ALK on Sugi Atlas →

209,721 patent compounds predicted against ALK, 123,585 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL19978 SCHEMBL19978 1.00 8/20
SCHEMBL19979 SCHEMBL19979 1.00 8/20
SCHEMBL97762 SCHEMBL97762 0.76 8/20
Crizotinib Crizotinib (SCHEMBL93829) 1.00 7/20
Crizotinib Crizotinib (SCHEMBL94020) 1.00 7/20
SCHEMBL63882 SCHEMBL63882 0.49 6/20
Semaxanib Semaxanib (SCHEMBL19571) 1.00 5/20
Semaxanib Semaxanib (SCHEMBL19572) 1.00 5/20
SCHEMBL19816 SCHEMBL19816 0.70 4/20
SCHEMBL19817 SCHEMBL19817 0.70 4/20
SCHEMBL20228 SCHEMBL20228 0.55 4/20
SCHEMBL20229 SCHEMBL20229 0.55 4/20
SCHEMBL57147 SCHEMBL57147 0.54 4/20
SCHEMBL100073 SCHEMBL100073 0.48 4/20
SCHEMBL19691 SCHEMBL19691 0.71 3/20
SCHEMBL19692 SCHEMBL19692 0.71 3/20
SCHEMBL58313 SCHEMBL58313 0.59 3/20
SCHEMBL58543 SCHEMBL58543 0.57 3/20
SCHEMBL98881 SCHEMBL98881 0.57 3/20
SCHEMBL60464 SCHEMBL60464 0.57 3/20

Clinical trials — most relevant to ALK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 PHASE3RECRUITING
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers PHASE2/PHASE3RECRUITING
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia PHASE2/PHASE3RECRUITING
Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) PHASE1/PHASE2NOT_YET_RECRUITING
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. PHASE2COMPLETED
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) PHASE2COMPLETED
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen PHASE1/PHASE2COMPLETED
MPDL3280A-treatment-IST-UMCG PHASE2UNKNOWN
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer PHASE2WITHDRAWN
Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer PHASE2UNKNOWN
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 PHASE2COMPLETED
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation PHASE2COMPLETED
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC PHASE2COMPLETED
Phase 1 Safety Study of ALK-001 in Healthy Volunteers PHASE1COMPLETED
A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase PHASE1COMPLETED
A Study of ASP1002 in Adults for Treatment of Solid Tumors PHASE1RECRUITING
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib nanRECRUITING
Primary Resistance Mechanisms of ALK TKIs nanNOT_YET_RECRUITING
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation. nanUNKNOWN
A Pilot Study on ALK Gene Mutations in Neuroblastoma nanUNKNOWN
The Research Plan of Taiwan Precision Medicine nanRECRUITING
Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy nanCOMPLETED
Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC nanCOMPLETED
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) nanCOMPLETED
Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test) nanCOMPLETED
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. nanCOMPLETED
Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance nanCOMPLETED
Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements nanCOMPLETED
Studying Tumor Samples From Young Patients With Neuroblastoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ALK binder may also engage these)

ProteinNameSimilarity
P0DV84 — 0.998 P0DV84 →
P97793 — 0.996 P97793 →
F1QVU0 — 0.983 F1QVU0 →
Q9BXP8 — 0.981 Q9BXP8 →
Q07105 — 0.976 Q07105 →
Q08DV9 — 0.976 Q08DV9 →
Q9GK68 — 0.976 Q9GK68 →
O77681 — 0.976 O77681 →
P17491 — 0.975 P17491 →
Q8K099 — 0.975 Q8K099 →
F8W3R9 — 0.974 F8W3R9 →
Q04999 — 0.974 Q04999 →
Q66NC0 — 0.974 Q66NC0 →
O60383 — 0.974 O60383 →
Q8JZL1 — 0.974 Q8JZL1 →
Q8K2W3 — 0.974 Q8K2W3 →
Q8R4K8 — 0.974 Q8R4K8 →
Q8N8Z6 — 0.974 Q8N8Z6 →
O14525 — 0.974 O14525 →
Q9WU72 — 0.974 Q9WU72 →
Q9H0X4 — 0.973 Q9H0X4 →
Q80XH4 — 0.973 Q80XH4 →
Q3UY90 — 0.973 Q3UY90 →
O75129 — 0.973 O75129 →
P09529 — 0.972 P09529 →
Q05909 — 0.972 Q05909 →
A0A286YEC0 — 0.972 A0A286YEC0 →
Q60696 — 0.972 Q60696 →
Q766D5 — 0.972 Q766D5 →
Q9JLC4 — 0.972 Q9JLC4 →